Raymond James & Associates Amicus Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	SELL	$11.78 - $13.86 $157,204 - $184,961	-13,345 Reduced 55.42%	10,735 $130,000
Q2 2023 Jul 25, 2023	BUY	$10.72 - $13.3 $258,137 - $320,264	24,080 New	24,080 $302,000
Q4 2022 Feb 08, 2023	BUY	$9.89 - $12.7 $101,599 - $130,467	10,273 New	10,273 $125,000
Q1 2022 May 11, 2022	SELL	$7.89 - $12.48 $218,450 - $345,533	-27,687 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$9.82 - $12.44 $14,327 - $18,149	1,459 Added 5.56%	27,687 $320,000
Q3 2021 Nov 02, 2021	SELL	$8.74 - $11.84 $73,319 - $99,325	-8,389 Reduced 24.23%	26,228 $250,000
Q2 2021 Aug 11, 2021	SELL	$8.71 - $10.72 $663,954 - $817,174	-76,229 Reduced 68.77%	34,617 $334,000
Q1 2021 May 14, 2021	BUY	$9.2 - $23.86 $305,430 - $792,128	33,199 Added 42.76%	110,846 $1.1 Million
Q4 2020 Feb 12, 2021	SELL	$13.47 - $24.89 $53,637 - $99,111	-3,982 Reduced 4.88%	77,647 $1.79 Million
Q3 2020 Nov 04, 2020	SELL	$12.89 - $15.89 $201,986 - $248,996	-15,670 Reduced 16.1%	81,629 $1.15 Million
Q2 2020 Jul 28, 2020	BUY	$8.86 - $15.69 $63,171 - $111,869	7,130 Added 7.91%	97,299 $1.47 Million
Q1 2020 Apr 21, 2020	BUY	$6.63 - $11.16 $44,421 - $74,772	6,700 Added 8.03%	90,169 $833,000
Q4 2019 Feb 12, 2020	BUY	$7.48 - $10.75 $78,704 - $113,111	10,522 Added 14.42%	83,469 $813,000
Q3 2019 Nov 07, 2019	BUY	$8.02 - $13.25 $136,500 - $225,515	17,020 Added 30.43%	72,947 $585,000
Q2 2019 Aug 06, 2019	BUY	$10.96 - $14.4 $62,987 - $82,756	5,747 Added 11.45%	55,927 $698,000
Q1 2019 May 06, 2019	BUY	$10.04 - $13.92 $121,825 - $168,905	12,134 Added 31.89%	50,180 $682,000
Q4 2018 Feb 11, 2019	SELL	$8.38 - $13.44 $122,901 - $197,111	-14,666 Reduced 27.82%	38,046 $364,000
Q3 2018 Nov 14, 2018	SELL	$11.6 - $16.54 $28,408 - $40,506	-2,449 Reduced 4.44%	52,712 $637,000
Q2 2018 Aug 14, 2018	SELL	$13.13 - $17.09 $12,657 - $16,474	-964 Reduced 1.72%	55,161 $862,000
Q1 2018 May 14, 2018	SELL	$13.76 - $17.12 $1.88 Million - $2.34 Million	-136,853 Reduced 70.92%	56,125 $844,000
Q4 2017 Feb 14, 2018	BUY	$12.51 - $16.24 $30,199 - $39,203	2,414 Added 1.27%	192,978 $2.78 Million
Q3 2017 Nov 13, 2017	BUY	$11.74 - $15.78 $2.24 Million - $3.01 Million	190,564	190,564 $2.87 Million

Others Institutions Holding FOLD

# of Institutions

312

Shares Held

312M

Call Options Held

516K

Put Options Held

833K

Vanguard Group Inc Valley Forge, PA

28.8M
Shares

$271 Million
0.01% of portfolio
Perceptive Advisors LLC New York, NY

28.1M
Shares

$264 Million
7.83% of portfolio
Black Rock Inc. New York, NY

24.4M
Shares

$229 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

24M
Shares

$226 Million
0.05% of portfolio
Avoro Capital Advisors LLC New York, NY

23.2M
Shares

$218 Million
3.72% of portfolio

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.64B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account